IGC Pharma Inc - Aset Bersih saben Siji Saham IGC

Net profit for IGC Pharma, Inc. (IGC) is constrained by strict FDA oversight and patent barriers within the cannabinoid sector. The consolidated book value per share on the GURU.Markets chart reflects the current 0.06 metric. IGC Pharma, Inc. (IGC) is focusing on clinical trials for Alzheimer's drugs, although geopolitical conflicts and sanctions significantly hinder the international logistics of biomaterials and joint research.

Book value per share reflects the size of the issuer's net assets minus all liabilities, allowing for an assessment of the actual capital attributable to a single security. By analyzing the book value per share trend, investors determine the company's resilience to liquidity shortages, which is critically important for IGC Pharma, Inc. (IGC) due to the absence of revenue and high development costs for CNS drugs.